Alto Neuro is commercializing pramipexole, a dopamine agonist with strong clinical data in depression, but poor tolerability due to nausea. By combining it with the antiemetic ondansetron, the company mitigates the key side effect holding the drug back from widespread use, unlocking its therapeutic potential.
To maximize market reach, Alto Neuro is simultaneously developing its lead drug as an add-on therapy for psychiatrists and as a standalone monotherapy for primary care physicians. This dual strategy caters to different prescriber behaviors and aims for broader, faster adoption upon approval by serving the full spectrum of patients and doctors.
Leveraging strong existing academic data on its drug's core component, Alto Neuro is taking a calculated risk. By using recent financing to launch a Phase 3 study before its Phase 2b trial concludes, the company aims to compress its development timeline and submit its approval package to the FDA much sooner than a sequential approach would allow.